# UK Research and Innovation

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/uk-research-and-innovation/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 54 |
| Citations | 282,292 |
| City | Swindon |
| Country | GB |
| Description | UK Research and Innovation is a research organisation in Swindon, GB. OpenAlex records 1,424 works and 282,292 citations for it. 296 researchers list it as their most recent affiliation. |
| Homepage | https://www.ukri.org |
| OpenAlex ID | https://openalex.org/I4210087105 |
| Region | England |
| Researchers | 296 |
| ROR ID | https://ror.org/001aqnf71 |
| Type | government |
| Works | 1,424 |

## University papers

- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://scholariq.org/papers/carboplatin-in-brca1-2-mutated-and-triple-negative-breast-cancer-brcaness/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial](https://scholariq.org/papers/intracranial-efficacy-and-survival-with-tucatinib-plus-trastuzumab-and/)
- [Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/abemaciclib-plus-trastuzumab-with-or-without-fulvestrant-versus-trastuzumab-plus/)

## University top topics

Showing 8 of 22.

- [Research Data Management Practices](https://scholariq.org/topics/research-data-management-practices/)
- [Scientific Computing and Data Management](https://scholariq.org/topics/scientific-computing-and-data-management/)
- [Ionosphere and magnetosphere dynamics](https://scholariq.org/topics/ionosphere-and-magnetosphere-dynamics/)
- [Climate variability and models](https://scholariq.org/topics/climate-variability-and-models/)
- [Atmospheric and Environmental Gas Dynamics](https://scholariq.org/topics/atmospheric-and-environmental-gas-dynamics/)
- [Geophysics and Gravity Measurements](https://scholariq.org/topics/geophysics-and-gravity-measurements/)
- [Semantic Web and Ontologies](https://scholariq.org/topics/semantic-web-and-ontologies/)
- [Botulinum Toxin and Related Neurological Disorders](https://scholariq.org/topics/botulinum-toxin-and-related-neurological-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.